What is the safest way to check current Bremelanotide (PT-141) pricing?

Use official brand pages first, then confirm the exact cash-pay or insured amount with the prescribing service and dispensing pharmacy.

Does insurance always cover Bremelanotide (PT-141)?

No. Coverage depends on the specific plan, indication, and whether prior authorization is approved. Some plans may require step therapy or documentation of medical necessity.

Are there manufacturer savings programs for Bremelanotide (PT-141)?

Many branded peptide therapies offer savings cards or patient assistance programs. Eligibility typically requires commercial insurance and may exclude government programs like Medicare or Medicaid.

Structured page family:Cost guide

Bremelanotide (PT-141) Cost Guide: Insurance, Cash Pay, and Savings

In the United States, Bremelanotide (PT-141) costs depend on brand, pharmacy, insurance design, and whether the patient qualifies for manufacturer savings programs.

Active Market

This page is designed for US treatment decisions and uses US-first pricing and savings sources.

Official pricing

Verify current pricing directly on official Vyleesi pages before starting, because list pricing, self-pay offers, and eligibility terms can change.

Cash-pay reality

Official cash-pay pricing varies by pharmacy and dose. Contact multiple pharmacies or use a prescription discount service for current rates.

Insurance coverage

Commercial coverage for Bremelanotide (PT-141) varies by plan and indication. Prior authorization is commonly required.

Savings and coupons

Manufacturer savings programs may reduce out-of-pocket cost for eligible commercially insured patients.

Prior Authorization

Prior authorization is common and may require documentation of diagnosis, prior treatments, and clinical need.

Price Breakdown

List price (monthly)

~$900-$1,200/month (4-8 doses)

Average wholesale price

~$850-$1,100/month

Pharmacy acquisition estimate

~$800-$1,000/month

Typical negotiated rate

~$600-$850/month

Price per dose

~$113-$150 per 1.75 mg dose

Annual cost at list price

~$10,800-$14,400

Pharmacy Price Comparison

Pharmacy	Price Range	Notes
Retail	$850-$1,200/month	Cash price
Specialty pharmacy	$800-$1,100/month	May offer better pricing

Insurance Coverage Landscape

Commercial plans

~30-40% for HSDD; many plans exclude sexual dysfunction

Medicare Part D

Rarely covered

Medicaid

Rarely covered

VA coverage

Case-by-case

TRICARE

Limited

Employer plan typical tier

Tier 3-4 if covered; often excluded entirely

Prior Authorization Guide

Required Documentation

•HSDD diagnosis (acquired, generalized)
•Premenopausal status
•Failed counseling/therapy
•Flibanserin trial (sometimes required)

Common Denial Reasons

•Plan excludes sexual dysfunction drugs
•Postmenopausal (not approved)
•Insufficient documentation
•Lifestyle factors not addressed

Appeal Template Points

•FDA-approved for acquired HSDD
•Premenopausal status confirmed
•Psychological intervention documented
•Medical condition affecting quality of life

Expected timeline: 1-2 weeks

Savings Programs and Patient Assistance

Vyleesi Savings Card

copay

Eligibility: Commercially insured

Savings: $0-$99/month

Income limit: None

Enrollment: simple

AMAG/Palatin program

Patient Assistance

manufacturer

Eligibility: Uninsured, ≤400% FPL

Savings: Free or reduced

Income limit: ≤400% FPL

Enrollment: moderate

Limited availability

Generic and Biosimilar Status

No generic currently available

Expected: No generic expected soon

Cost by Dose

Dose/Regimen	Monthly	Annual
1.75 mg as needed (4 doses/month)	$900	$10,800
1.75 mg as needed (8 doses/month)	$1,200	$14,400

Annual Cost Projection

Year 1

$0-$14,400

Year 2

$0-$14,400

Year 3

$0-$14,400

Assumptions

•As-needed dosing
•Insurance variable

Cost-Saving Strategies

1.Start with 4 doses/month to assess response before increasing
2.Vyleesi savings card for commercially insured
3.Check if employer plan has any sexual dysfunction coverage
4.Document all prior interventions for prior auth

International Price Comparison

Country	Price Range	Notes
UK	Limited availability	Not widely marketed

Need help comparing bremelanotide (pt-141) paths?

Use the provider matcher to package treatment interest, insurance, budget, urgency, and state context before you commit to a prescribing path.

Find a bremelanotide provider

Next Step

Use the cost calculator

Use provider matching when you need help comparing insured and self-pay treatment paths.

Open tool →

Retention Path

Join the Bremelanotide (PT-141) tracker waitlist

Capture refill timing, weekly dose history, and symptom notes in one planned workflow.

View tracker landing →

Trust Summary

Reviewed 2026-04-27 by PeptideScholar editorial review. This page currently cites 3 official sources.

Pricing, savings eligibility, and coverage rules can change quickly. Verify all current figures and terms directly on official brand pages before acting.

Bremelanotide (PT-141) Cost FAQ

Sources

1. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.
J Womens Health (Larchmt) • 2022
Claim type: clinical
View source →
2. Bremelanotide: First Approval.
Drugs • 2019
Claim type: review
View source →
3. FDA Information on Bremelanotide (PT-141)
FDA • 2026
Claim type: regulatory
View source →

This content is for informational purposes only and does not constitute medical advice.